Literature DB >> 15865607

Increased expression of histone deacetylase 2 is found in human gastric cancer.

Jaehwi Song1, Ji Heon Noh, Jong Heun Lee, Jung Woo Eun, Young Min Ahn, Su Young Kim, Sug Hyung Lee, Won Sang Park, Nam Jin Yoo, Jung Young Lee, Suk Woo Nam.   

Abstract

Accumulated evidence has established that aberrant regulation of histone deacetylases (HDACs) is one of the major causes of the development of human malignancies. Among different iso-enzymes of HDAC and sirtuins grouped as the HDAC super family, little is known as to how histone deacetylase 2 (HDAC2) causes carcinogenesis in solid tumors. Here, in order to investigate the possible role of HDAC2 in gastric carcinogenesis, we analyzed the expression of HDAC2 in 71 gastric adenocarcinomas by immunohistochemistry. Moderate to strong expression of HDAC2 was found in 44 (62%) out of a total of 71 tumors. The majority of positive tumors, which were detected in the nucleus but not in normal gastric epithelium, did not express HDAC2 or showed only weak positive staining. Interestingly, we also noted that HDAC2 expression appeared to be associated with tumor aggressiveness as HDAC2 expression was observed to be statistically significant in advanced gastric cancer (P=0.0023, Chi-square test) and in positive lymph node metastasis (P=0.0713, Chi-square test). Taken together, these results suggest that HDAC2 may play an important role in the aggressiveness of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865607     DOI: 10.1111/j.1600-0463.2005.apm_04.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  105 in total

Review 1.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 3.  Epigenetic alterations in aging.

Authors:  Susana Gonzalo
Journal:  J Appl Physiol (1985)       Date:  2010-05-06

Review 4.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

Review 5.  Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.

Authors:  Mahmoud Alhosin; Tanveer Sharif; Marc Mousli; Nelly Etienne-Selloum; Guy Fuhrmann; Valérie B Schini-Kerth; Christian Bronner
Journal:  J Exp Clin Cancer Res       Date:  2011-04-15

Review 6.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

Review 7.  Isoform-selective histone deacetylase inhibitors.

Authors:  Anton V Bieliauskas; Mary Kay H Pflum
Journal:  Chem Soc Rev       Date:  2008-05-08       Impact factor: 54.564

8.  The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.

Authors:  Sun Ea Choi; Sujith V W Weerasinghe; Mary Kay H Pflum
Journal:  Bioorg Med Chem Lett       Date:  2011-08-12       Impact factor: 2.823

9.  The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

Authors:  Brian M Zeglis; NagaVaraKishore Pillarsetty; Vadim Divilov; Ronald A Blasberg; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

10.  Effects and mechanisms of silibinin on human hepatoma cell lines.

Authors:  John-J Lah; Wei Cui; Ke-Qin Hu
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.